Annual Cash & Cash Equivalents
$428.43 M
-$538.35 M-55.68%
31 December 2023
Summary:
Sarepta Therapeutics annual cash & cash equivalents is currently $428.43 million, with the most recent change of -$538.35 million (-55.68%) on 31 December 2023. During the last 3 years, it has fallen by -$1.69 billion (-79.75%). SRPT annual cash & cash equivalents is now -79.75% below its all-time high of $2.12 billion, reached on 31 December 2021.SRPT Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$197.85 M
-$185.77 M-48.42%
30 September 2024
Summary:
Sarepta Therapeutics quarterly cash and cash equivalents is currently $197.85 million, with the most recent change of -$185.77 million (-48.42%) on 30 September 2024. Over the past year, it has dropped by -$230.57 million (-53.82%). SRPT quarterly cash and cash equivalents is now -90.65% below its all-time high of $2.12 billion, reached on 31 December 2021.SRPT Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SRPT Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -53.8% |
| 3 y3 years | -79.8% | -90.7% |
| 5 y5 years | -48.7% | -76.3% |
SRPT Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -79.8% | at low | -90.7% | at low |
| 5 y | 5 years | -79.8% | at low | -90.7% | at low |
| alltime | all time | -79.8% | >+9999.0% | -90.7% | +8502.4% |
Sarepta Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $197.85 M(-48.4%) |
| June 2024 | - | $383.62 M(-10.2%) |
| Mar 2024 | - | $427.29 M(-0.3%) |
| Dec 2023 | $428.43 M(-55.7%) | $428.43 M(-20.9%) |
| Sept 2023 | - | $541.93 M(-36.4%) |
| June 2023 | - | $851.93 M(-2.3%) |
| Mar 2023 | - | $871.67 M(-9.8%) |
| Dec 2022 | $966.78 M(-54.3%) | $966.78 M(-6.9%) |
| Sept 2022 | - | $1.04 B(+19.6%) |
| June 2022 | - | $868.57 M(-29.6%) |
| Mar 2022 | - | $1.23 B(-41.7%) |
| Dec 2021 | $2.12 B(+40.8%) | $2.12 B(+32.3%) |
| Sept 2021 | - | $1.60 B(-5.8%) |
| June 2021 | - | $1.70 B(+14.5%) |
| Mar 2021 | - | $1.48 B(-1.4%) |
| Dec 2020 | $1.50 B(+79.9%) | $1.50 B(+1.9%) |
| Sept 2020 | - | $1.47 B(-10.1%) |
| June 2020 | - | $1.64 B(-7.0%) |
| Mar 2020 | - | $1.76 B(+111.3%) |
| Dec 2019 | $835.08 M(+125.2%) | $835.08 M(+15.2%) |
| Sept 2019 | - | $724.83 M(-10.4%) |
| June 2019 | - | $808.59 M(+10.4%) |
| Mar 2019 | - | $732.19 M(+97.4%) |
| Dec 2018 | $370.83 M(-38.2%) | $370.83 M(+76.8%) |
| Sept 2018 | - | $209.70 M(-48.9%) |
| June 2018 | - | $410.38 M(-26.4%) |
| Mar 2018 | - | $557.23 M(-7.1%) |
| Dec 2017 | $599.69 M(+389.9%) | $599.69 M(-2.9%) |
| Sept 2017 | - | $617.63 M(+266.9%) |
| June 2017 | - | $168.35 M(-38.7%) |
| Mar 2017 | - | $274.72 M(+124.4%) |
| Dec 2016 | $122.42 M(+52.4%) | $122.42 M(-69.0%) |
| Sept 2016 | - | $395.14 M(+253.4%) |
| June 2016 | - | $111.82 M(+194.3%) |
| Mar 2016 | - | $38.00 M(-52.7%) |
| Dec 2015 | $80.30 M(+9.2%) | $80.30 M(+43.9%) |
| Sept 2015 | - | $55.82 M(-19.7%) |
| June 2015 | - | $69.54 M(-6.6%) |
| Mar 2015 | - | $74.44 M(+1.2%) |
| Dec 2014 | $73.55 M(-71.4%) | $73.55 M(+40.6%) |
| Sept 2014 | - | $52.30 M(-49.1%) |
| June 2014 | - | $102.75 M(+109.3%) |
| Mar 2014 | - | $49.10 M(-80.9%) |
| Dec 2013 | $256.96 M(+36.9%) | $256.96 M(-6.1%) |
| Sept 2013 | - | $273.64 M(+75.2%) |
| June 2013 | - | $156.19 M(-7.0%) |
| Mar 2013 | - | $167.92 M(-10.5%) |
| Dec 2012 | $187.66 M(+370.3%) | $187.66 M(+394.0%) |
| Sept 2012 | - | $37.99 M(+55.1%) |
| June 2012 | - | $24.49 M(-19.9%) |
| Mar 2012 | - | $30.57 M(-23.4%) |
| Dec 2011 | $39.90 M(+18.8%) | $39.90 M(-13.9%) |
| Sept 2011 | - | $46.36 M(-14.5%) |
| June 2011 | - | $54.19 M(+132.7%) |
| Mar 2011 | - | $23.28 M(-30.7%) |
| Dec 2010 | $33.59 M | $33.59 M(-6.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2010 | - | $35.97 M(-2.1%) |
| June 2010 | - | $36.74 M(-11.3%) |
| Mar 2010 | - | $41.44 M(-14.2%) |
| Dec 2009 | $48.27 M(+331.3%) | $48.27 M(-4.0%) |
| Sept 2009 | - | $50.27 M(+150.9%) |
| June 2009 | - | $20.04 M(-19.0%) |
| Mar 2009 | - | $24.72 M(+120.9%) |
| Dec 2008 | $11.19 M(-54.9%) | $11.19 M(-20.5%) |
| Sept 2008 | - | $14.08 M(-23.9%) |
| June 2008 | - | $18.51 M(-7.3%) |
| Mar 2008 | - | $19.96 M(-19.5%) |
| Dec 2007 | $24.80 M(+23.0%) | $24.80 M(+542.3%) |
| Sept 2007 | - | $3.86 M(-58.3%) |
| June 2007 | - | $9.26 M(-38.1%) |
| Mar 2007 | - | $14.96 M(-25.8%) |
| Dec 2006 | $20.16 M(-41.7%) | $20.16 M(-21.2%) |
| Sept 2006 | - | $25.58 M(-19.5%) |
| June 2006 | - | $31.76 M(-13.8%) |
| Mar 2006 | - | $36.87 M(+6.6%) |
| Dec 2005 | $34.60 M(+107.7%) | $34.60 M(+25.6%) |
| Sept 2005 | - | $27.56 M(+0.8%) |
| June 2005 | - | $27.35 M(-20.4%) |
| Mar 2005 | - | $34.36 M(+106.3%) |
| Dec 2004 | $16.65 M(+33.0%) | $16.65 M(+34.9%) |
| Sept 2004 | - | $12.34 M(+11.7%) |
| June 2004 | - | $11.04 M(+27.1%) |
| Mar 2004 | - | $8.69 M(-30.6%) |
| Dec 2003 | $12.52 M(+20.6%) | $12.52 M(+91.8%) |
| Sept 2003 | - | $6.53 M(-28.1%) |
| June 2003 | - | $9.08 M(+26.6%) |
| Mar 2003 | - | $7.17 M(-30.9%) |
| Dec 2002 | $10.38 M(-6.2%) | $10.38 M(-17.5%) |
| Sept 2002 | - | $12.59 M(-6.4%) |
| June 2002 | - | $13.45 M(-55.0%) |
| Mar 2002 | - | $29.89 M(+170.0%) |
| Dec 2001 | $11.07 M(-57.3%) | $11.07 M(-55.0%) |
| Sept 2001 | - | $24.61 M(-12.5%) |
| June 2001 | - | $28.13 M(+27.9%) |
| Mar 2001 | - | $22.00 M(-15.0%) |
| Dec 2000 | $25.90 M(+197.7%) | $25.90 M(-12.4%) |
| Sept 2000 | - | $29.55 M(+325.3%) |
| June 2000 | - | $6.95 M(-27.5%) |
| Mar 2000 | - | $9.58 M(+10.1%) |
| Dec 1999 | $8.70 M(+2.4%) | $8.70 M(+262.5%) |
| Sept 1999 | - | $2.40 M(-45.5%) |
| June 1999 | - | $4.40 M(-34.3%) |
| Mar 1999 | - | $6.70 M(-21.2%) |
| Dec 1998 | $8.50 M(-51.7%) | $8.50 M(-22.0%) |
| Sept 1998 | - | $10.90 M(-17.4%) |
| June 1998 | - | $13.20 M(-16.5%) |
| Mar 1998 | - | $15.80 M(-10.2%) |
| Dec 1997 | $17.60 M(+486.7%) | $17.60 M(-4.9%) |
| Sept 1997 | - | $18.50 M(+5.1%) |
| June 1997 | - | $17.60 M(+665.2%) |
| Mar 1997 | - | $2.30 M |
| Dec 1996 | $3.00 M | - |
FAQ
- What is Sarepta Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Sarepta Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of SRPT is $428.43 M
What is the all time high annual cash & cash equivalents for Sarepta Therapeutics?
Sarepta Therapeutics all-time high annual cash & cash equivalents is $2.12 B
What is Sarepta Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of SRPT is $197.85 M
What is the all time high quarterly cash and cash equivalents for Sarepta Therapeutics?
Sarepta Therapeutics all-time high quarterly cash and cash equivalents is $2.12 B
What is Sarepta Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, SRPT quarterly cash and cash equivalents has changed by -$230.57 M (-53.82%)